PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+10.98%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.21B
AUM Growth
+$1.21B
(+2.9%)
Cap. Flow
+$8.35M
Cap. Flow
% of AUM
0.69%
Top 10 Holdings %
Top 10 Hldgs %
87.78%
Holding
31
New
2
Increased
12
Reduced
3
Closed
1
Top Buys
| 1 |
STAAR Surgical
STAA
|
$6.86M |
| 2 |
Gossamer Bio
GOSS
|
$4.32M |
| 3 |
NovoCure
NVCR
|
$1.97M |
| 4 |
eHealth
EHTH
|
$1.92M |
| 5 |
Relmada Therapeutics
RLMD
|
$1.23M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$5.33M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
$4.11M |
| 3 |
ALIM
Alimera Sciences, Inc.
ALIM
|
$544K |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$432K |
Sector Composition
| 1 | Healthcare | 97.91% |
| 2 | Financials | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $178M | 14.75% | 1,831,035 -54,776 | -3% | -$5.33M |
|
|
RVNC
2
DELISTED
Revance Therapeutics, Inc.
RVNC
| $170M | 14.06% | 5,270,209 -13,400 | -0.3% | -$432K |
|
3
United Therapeutics
UTHR
$13.8B
| $141M | 11.64% | 627,514 +2,100 | +0.3% | +$470K |
|
4
Amicus Therapeutics
FOLD
$2.34B
| $117M | 9.67% | 10,524,022 +30,300 | +0.3% | +$336K |
|
5
Biogen
BIIB
$19.4B
| $106M | 8.78% | 381,282 +1,200 | +0.3% | +$334K |
|
6
Insmed
INSM
$28.8B
| $100M | 8.32% | 5,889,491 +18,200 | +0.3% | +$310K |
|
|
7
STAAR Surgical
STAA
$1.36B
| $86.2M | 7.14% | 1,347,322 +107,245 | +9% | +$6.86M |
|
8
Prothena Corp
PRTA
$441M
| $80.6M | 6.68% | 1,663,777 +5,200 | +0.3% | +$252K |
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $45.3M | 3.75% | 2,405,793 +29,424 | +1% | +$554K |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $36.1M | 2.99% | 859,517 +3,000 | +0.4% | +$126K |
|
|
11
eHealth
EHTH
$118M
| $25.2M | 2.09% | 2,689,379 +204,900 | +8% | +$1.92M |
|
12
Align Technology
ALGN
$10.3B
| $24.9M | 2.07% | 74,605 | – | – |
|
13
Karyopharm Therapeutics
KPTI
$61.7M
| $22.1M | 1.83% | 5,675,876 +20,200 | +0.4% | +$78.6K |
|
14
Alkermes
ALKS
$4.78B
| $17M | 1.41% | 603,400 | – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.9M | 1.07% | 612,600 | – | – |
|
|
PRVB
16
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $9.42M | 0.78% | 390,800 | – | – |
|
17
AnaptysBio
ANAB
$569M
| $9.38M | 0.78% | 431,224 +200 | +0% | +$4.35K |
|
|
18
Gossamer Bio
GOSS
$562M
| $4.37M | 0.36% | 3,465,152 +3,427,402 | +9,079% | +$4.32M |
|
19
Cytokinetics
CYTK
$4.23B
| $3.93M | 0.33% | 111,717 | – | – |
|
20
Travere Therapeutics
TVTX
$1.56B
| $3.73M | 0.31% | 166,069 | – | – |
|
|
21
Vanda Pharmaceuticals
VNDA
$279M
| $3.28M | 0.27% | 482,697 -604,910 | -56% | -$4.11M |
|
22
Kezar Life Sciences
KZR
$28.9M
| $2.05M | 0.17% | 656,200 | – | – |
|
|
23
NovoCure
NVCR
$1.38B
| $1.97M | 0.16% | +32,790 | New | +$1.97M |
|
|
GRTS
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.85M | 0.15% | 666,127 | – | – |
|
25
Aldeyra Therapeutics
ALDX
$351M
| $1.6M | 0.13% | 160,800 | – | – |
|